Research Article

IRS1, TCF7L2, ADRB1, PPARG, and HHEX Polymorphisms Associated with Atherogenic Risk in Mexican Population

B. I. Estrada-Velasco,¹ M. Cruz,² V. Madrid-Marina,¹ G. A. Martínez-Nava,¹ J. Gomez-Zamudio,² and A. I. Burguete-García¹

¹ Centro de Enfermedades Infecciosas, Instituto Nacional de Salud Pública, Avenida Universidad 655, Santa María Ahuacatlán, Cuernavaca, 62100 Cuernavaca, MOR, Mexico

² Unidad de Investigación Médica en Bioquímica, Hospital de Especialidades, IMSS, Avenida Cuauhtémoc 330, Doctores, Cuauhtémoc, CMN Siglo XXI, 06720 México, DF, Mexico

Correspondence should be addressed to A. I. Burguete-García; aburguete@insp.mx

Received 8 May 2013; Accepted 21 October 2013

Academic Editor: Ali Rizvi

Copyright © 2013 B. I. Estrada-Velasco et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. We aimed to explore the association between polymorphisms of *IRS1* (rs1801278), *TCF7L2* (rs7903146 and rs12255372), *ADRB1* (rs1801253), *PPARG* (rs1801282), and *HHEX* (rs5015480) genes with atherogenic risk (AI = Total cholesterol/HDL) in MetS, T2D, and healthy populations from the Mexican Social Security Institute. **Methodology and Results.** Four hundred thirty-five MetS, 517 T2D, and 547 healthy individuals were selected. The association between the SNPs and the atherogenic index was evaluated by multiple linear regression and multinomial logistic regression models. The *ADRB1* gene showed a statistically significant association with high-risk atherogenic index, OR = 2.94 (IC 95% 1.64–5.24; $P < 0.0001$) for the Arg/Gly variant, under the dominant model an OR = 2.96 (IC 95% 1.67–5.25; $P < 0.0001$), and under the Log additive model an OR = 2.52 (IC 95% 1.54–4.15; $P < 0.0001$). **Conclusions.** The Arg389Gly polymorphism of the *ADRB1* gene may be a worthy biological marker to predict the risk of developing cardiovascular diseases given a high-risk atherogenic index.

1. Introduction

The metabolic syndrome (MetS) is a group of metabolic disorders that directly promote the development of cardiovascular diseases (CVD) [1, 2]. One of these disorders, insulin resistance (IR) [3], is at the core of the physiopathology of the MetS and type 2 diabetes (T2D). Lipid metabolism is affected by the consequences of IR, culminating in the MetS characteristic lipid disorders: IR leads to high levels of very low density lipoproteins (VLDL) that cause high triglyceride levels and low HDL-c levels, a profile known as atherogenic lipoprotein phenotype [4]. IR can, thus, be associated with fatty acid metabolism disequilibrium [5].

The last two decades have seen a marked increase in the number of people with MetS worldwide [6]. In Mexico, the prevalence of MetS under the ATP III, AHA/NHLBI, and IDF criteria was 36.8%, 41.6%, and 49.8%, respectively [7].

Several susceptibility loci for MetS component traits have been soundly identified to play a role in the risk of IR [8], obesity [9, 10], hypertriglyceridemia, and low HDL-c levels [11, 12]. The *IRS1* gene Gly972Arg polymorphism affects the PI3-k/AKT/GSK3 signaling pathway, producing IR due to a decrease in the ability of insulin to transport glucose, translocation of the glucose transporter, and glycogen synthesis [13]. This polymorphism has been associated with elevated serum triglyceride, low HDL-c levels, high free fatty acid levels, and elevated systolic blood pressure [14]. Variants in the *TCF7L2*, *SLC30A8*, *HHEX*, *FTO*, *PPARG*, and *KCNJ11* genes are associated with T2D and cardiovascular disease risk [15–17]. Polymorphisms in the beta-adrenergic receptors genes are associated with cardiovascular and metabolic phenotypes. The β adrenergic receptors play a major role in energy expenditure through thermogenesis stimulation [18]. The aim of this study was to analyze the association between the *IRS1*

(rs1801278), TCF7L2 (rs7903146 and rs12255372), ADRB1 (rs1801253), PPARG (rs1801282), and HHEX (rs5015480) polymorphisms with IR, lipid profile, and atherogenic risk.

2. Methodology

2.1. Design and Study Population. In a cross-sectional study, we recruited 431 patients with MetS and 517 patients with T2D defined according to the criteria of the American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement (AHA/NHLBI) [2] and the American Diabetes Association (ADA), respectively, and 547 health individuals (without MetS or T2D) between 35 and 65 years old. The AHA/NHLBI criteria are: waist circumference ≥ 102 cm for men and ≥ 88 cm for women, fasting glucose ≥ 100 mg/dL, systolic blood pressure (SBP) ≥ 130 mm Hg, diastolic blood pressure (DBP) ≥ 85 mm Hg, HDL-c < 40 mg/dL for men and < 50 mg/dL for women, and triglycerides ≥ 150 mg/dL. The study population was selected at the IMSS Medical Center of Mexico City. The inclusion criterion for healthy individuals was absence of a family history of T2D among parents, siblings, or offspring. Written consent was obtained from the participants, and the protocol was approved by the Institutional Review Board (IRB) of the National Public Health Institute and the National Committee of the IMSS.

2.2. Biochemical and Anthropometric Measurements. All participants answered a questionnaire used for collecting socioeconomic data, as well as family history of diabetes and other diseases. The following anthropometric measurements were performed: weight (kg), height (cm), body mass index (BMI) (kg/m^2), waist (cm) and hip (cm) circumference, and the waist/hip ratio (WHR). SBP and DBP were measured with a mercury column sphygmomanometer (American Diagnostic Inc., New York), after the patients had rested and were seated for at least 5 minutes. A blood sample was obtained from all participants, after a 12-hour fast, for the determination of biochemical profiles of glucose (mg/dL), total cholesterol, LDL cholesterol (LDL-C, mg/dL), HDL cholesterol (HDL-C, mg/dL), and triglycerides (mg/dL). These parameters were determined by the ILab 30 Clinical Chemistry System instrument (Instrumentation Laboratory, Barcelona, Spain). IR was estimated by means of the Homeostasis Model Assessment-Insulin Resistance, mmol/pmol (HOMA-IR), and the atherogenic index (AI) was estimated with the following formula: $\text{AI} = \text{Total cholesterol/HDL-c}$, with a cut-off point for cardiovascular risk of > 4.5 for women and > 5 for men [19].

2.3. Genotyping. DNA extraction from peripheral vein blood samples was carried out by a semiautomated method with the commercial QIAamp DNA Blood Mini/Kit column purification kits (Qiagen, Germany). DNA integrity was determined by 0.8% agarose gel electrophoresis, stained with ethidium bromide, and visualized through the Gel Doc 2000 equipment (BIORADCA, USA). DNA concentration was determined by spectrophotometry, using the VICTOR³ 1420 equipment (Perkin-Elmer, Germany). Single nucleotide polymorphism (SNP) analysis was carried out in duplicate

TABLE 1: SNP, rs number, and GenBank number.

SNP	rs	GenBank no.
IRS1	rs1801278	S62539
TCF7L2	rs7903146	NT_030059 ABBA01063000
TCF7L2	rs12255372	NT_030059 ABBA01063000
ADRB1	rs1801253	NT_030059.12 ABBA01062983
PPARG	rs1801282	U79012 015869 ABBA01025204
HHEX	rs5015480	NT_030059.12 ABBA01021892

with real-time PCR TaqMan technology (Applied Biosystems 7900HT equipment, Foster City, California, USA), following standardized techniques. Studied SNPs were: *IRS1* (rs1801278), *TCF7L2* (rs7903146 and rs12255372), *ADRB1* (rs1801253), *PPARG* (rs1801282), and *HHEX* (rs5015480) (Table 1). For quality control (QC) of the genotyping, we used a call rate of 0.99 for cases and controls; all the samples with 0.99 call rate were analyzed by two independent researchers who scored genotype results using the graphical view (SD 2.1.1, Applied Biosystems), and all differences were resolved by discussions between the independent researchers and by rerunning the samples if necessary. If the concordance was less than 99.99%, this was considered as a missing value. Only 3.35% of the samples had less than 99.99% concordance.

In order to control the possible effect of population stratification, a panel of ancestry informative markers (AIM) was also genotyped. The panel was integrated by 27 AIMS (rs2814778, rs723822, rs1008984, rs1435090, rs17203, rs768324, rs719776, rs1112828, rs1403454, rs3340, rs2077681, rs1935946, rs1320892, rs1373302, rs2695, rs1980888, rs1327805, rs2207782, rs1487214, rs2078588, rs724729, rs292932, rs1369290, rs386569, rs718092, rs878825, and rs16383) taken from a previous assessed ancestry panel [20]. These markers showed differences in allele frequency between European 30%, African 5%, and Amerindian populations 65%, in Mexican population in a previous report of our research group [20].

2.4. Statistical Analysis. In order to compare the relevant variants between cases and controls, the Kruskal-Wallis test for group comparison was used for continuous variables, and the chi square test (χ^2) was used for categorical data. Hardy-Weinberg equilibrium was evaluated for each variant under study. A multiple linear regression analysis was performed to evaluate the effects of the selected variants on the IR biochemical markers (glucose, insulin, and HOMA-IR) and the atherogenic profile biomarkers (total cholesterol, LDL-c, HDL-c, and triglycerides). A multinomial logistic regression was also carried out to evaluate the effect of each and every variant on AI risk ($\text{AI} = \text{Total cholesterol/HDL}$; with the following cut-off points: low risk < 4.5 for women and < 5 for men, medium risk 4.5–7 for women and 5–9 for men, and high risk > 7 for women and > 9 for men) [18] for the different genotypes in the codominant, dominant, recessive, and log-additive heritability models. All models were adjusted for age, sex, disease status, BMI, and ancestry percentage. The study's power average was 80%. The possibility of multiple testing burden was avoided by using the Bonferroni method (0.05/42

TABLE 2: Sociodemographics, clinics, and ancestry characteristics.

Variables	Low risk AI (711)	Medium risk AI (728)	High risk AI (56)	P value
Age	48.17 ± 8.61	46.86 ± 7.98	44.68 ± 7.98	0.0009*
Total cholesterol (mg/dL)	190.93 ± 39.92	222.63 ± 51.35	261.84 ± 65.86	0.0001*
LDL-c (mg/dL)	119.21 ± 30.88	140.08 ± 37.32	156.14 ± 50.88	0.0001*
HDL-c (mg/dL)	49.93 ± 12.97	38.89 ± 10.44	29.59 ± 7.36	0.0001*
Triglycerides (mg/dL)	158.95 ± 77.54	263.56 ± 160.32	361.75 ± 246.11	0.0001*
Disease status (%)				
Health	45.71	28.16	30.36	<0.0001**
Metabolic syndrome	17.02	39.56	39.29	
Type 2 diabetes	37.37	32.28	30.36	
BMI	28.75 ± 4.47	29.15 ± 4.14	29.48 ± 5.43	0.07*
SBP (mm Hg)	119.28 ± 13.42	120.65 ± 12.33	119.21 ± 10.79	0.03*
DBP (mm Hg)	75.5 ± 8.63	76.10 ± 8.15	77.46 ± 7.99	0.21*
Glucose (mg/dL)	118.41 ± 56.90	127.29 ± 72.19	120.14 ± 56.96	0.07*
Insulin (pmol/L)	11.73 ± 8.89	12.27 ± 7.28	13.44 ± 9.23	0.009*
HOMA-IR	3.73 ± 5.23	4.07 ± 4.96	4.20 ± 4.32	0.005*
Ancestry contribution				
African	0.03 ± 0.021	0.03 ± 0.023	0.03 ± 0.030	0.69*
European	0.32 ± 0.11	0.33 ± 0.10	0.32 ± 0.09	0.58*
Amerindian	0.65 ± 0.12	0.64 ± 0.11	0.65 ± 0.10	0.55*
Sex (%)				
F	47.12	40.66	57.14	0.007**
M	52.88	59.34	42.86	
Educational level (%)				
Elementary or lower	31.16	30.70	31.91	0.88**
Middle school	27.08	28.07	31.91	
High school	19.21	20.61	21.28	
College or higher	22.54	20.61	14.89	

Data shown in means and SD. F: female, M: male, SBP: systolic blood pressure, DBP: diastolic blood pressure. * Kruskal Wallis *P* value, ** Chi square *P* value.

comparisons = $P \leq 0.001$ for linear regression and 0.05/12 comparisons = $P \leq 0.004$ for multinomial logistic regression) and false-positive report probability (FPRP) for correction of multiple comparisons [21]. The STATA SE version 12.0 statistical package software (College Station, TX) was used for the analyses.

3. Results

The general characteristics of the groups studied are shown in Table 2. The Low risk AI group had lower levels in mg/dL to total cholesterol (190.93 ± 39.92 , $P = 0.0001$), LDL (119.21 ± 30.88 , $P = 0.0001$), triglycerides (158.95 ± 77.54 , $P = 0.0001$), glucose (118.41 ± 56.90 , $P = 0.07$), and insulin (11.73 ± 8.89 , $P = 0.009$), compared to medium and high risk AI groups. There was no difference in BMI between the three groups. The ancestry percentage was similar in the three groups, with the Amerindian group having the highest percentage, followed by the European group, whereas the African group had a minimum percentage.

Table 3 shows that all studied polymorphisms are in Hardy-Weinberg equilibrium. For all polymorphisms, genotype and allele frequencies were similar in the three groups

of risk AI. All polymorphisms were in HW equilibrium in the control group of low risk AI (*IRS1* $P = 0.95$, *TCF7L2* rs12255372 $P = 0.42$, rs7903146 $P = 0.16$, *PPARG* $P = 0.14$, *ADRB1* $P = 0.31$, and *HHEX* $P = 0.95$).

In order to evaluate the variant's effect on the IR biochemical and on atherogenic profile biomarkers, measured by total cholesterol, LDL-c, HDL-c, triglycerides, glucose, insulin, and HOMA-IR, a multiple linear regression analysis was carried out according to the codominant, dominant, and recessive models, adjusted for age, sex, BMI, ancestry percentage, and disease status. No statistically significant associations were found (data not shown).

A possible association between the polymorphic variants and other characteristics such as SBP, DBP, and WHR, was assessed through a multiple linear regression analysis adjusted for age, sex, BMI, ancestry percentage, and disease status. However, the results of this analysis did not show any potential association (data not shown).

Table 4 shows multinomial logistic regression results that evaluates the effect of each and every variant on the risk of presenting an AI category (medium or high risk; low risk was considered the reference category) for the log-additive model, adjusted for age, sex, BMI, disease status, and ancestry

TABLE 3: Genotype frequencies and Hardy-Weinberg equilibrium.

	Medium risk AI		High risk AI		Controls	
	<i>n</i>	%	<i>n</i>	%	<i>n</i>	%
IRS1 (rs1801278) Gly972Arg						
G/G	6570	92.46	477	90.4	6377	92.70
G/A	51	7.17	5	9.6	49	7.13
A/A	3	0.42	0	0	1	0.14
G		0.96		0.96		0.95
A		0.04		0.04		0.05
HW* (<i>P</i> value)						0.95
TCF7L2 (rs12255372)						
G/G	507	74.99	343	70.8	512	75.85
G/T	156	23	131	27.1	149	22.10
T/T	14	2.1	1	2.1	14	2.07
G		0.86		0.85		0.87
T		0.13		0.15		0.12
HW (<i>P</i> value)						0.42
TCF7L2 (rs7903146)						
C/C	477	72.96	33	66	466	72.83
C/T	179	23.47	12	24	180	24.58
T/T	24	3.57	5	10	22	2.59
C		0.83		0.78		0.83
T		0.17		0.25		0.17
HW (<i>P</i> value)						0.17
PPARG (rs1801282) Pro12Ala						
C/C	556	78.2	37	78.7	502	73.8
C/G	142	20	8	17	159	23.4
G/G	13	1.8	2	4.2	19	2.8
C		0.88		0.87		0.86
G		0.12		0.13		0.14
HW (<i>P</i> value)						0.14
ADRB1 (rs1801253) Arg389Gly						
C/C	555	76.6	32	57.1	557	78.8
C/G	157	21.75	23	41.1	144	20.4
G/G	12	1.6	1	1.8	6	0.8
C		0.88		0.78		0.89
G		0.12		0.22		0.11
HW (<i>P</i> value)						0.31
HHEX (rs5015480)						
T/T	267	37.8	18	32.7	266	37.36
T/C	341	48.3	28	50.9	316	47.93
C/C	98	13.9	9	16.4	93	14.71
T		0.62		0.58		0.61
C		0.38		0.42		0.38
HW (<i>P</i> value)						0.95

*HW: Hardy-Weinberg equilibrium.

percentage; only the *ADRB1* polymorphism (Arg389Gly) showed a statistically significant association with high-risk AI (OR = 2.52, IC 95% 1.54–4.15; $P < 0.0001$).

Finally, the multinomial logistic regression results that evaluate the effect *ADRB1* variant on the risk of presenting an AI category (medium or high risk; low risk was considered

TABLE 4: Association of polymorphisms with atherogenic index.

SNP	Medium risk AI ORa (CI)	<i>P</i>	High risk AI ORa (CI)	<i>P</i>
IRS1 rs1801279				
Log additive	1.00 (0.68, 1.47)	0.99	1.24 (0.49, 3.13)	0.65
TCF7L2 rs12255372				
Log additive	0.95 (0.76, 1.19)	0.67	1.15 (0.64, 2.08)	0.63
TCF7L2 rs7903146				
Log additive	0.93 (0.76, 1.15)	0.51	1.35 (0.82, 2.21)	0.24
PPARG rs1801282				
Log additive	0.81 (0.65, 1.01)	0.06	0.89 (0.48, 1.65)	0.71
ADRB1 rs1801253				
Log additive	1.16 (0.91, 1.47)	0.22	2.52 (1.54, 4.15)	<0.0001*
HHEX rs5015480				
Log additive	1.03 (0.88, 1.22)	0.68	1.24 (0.82, 1.87)	0.30

Adjusted for age, sex, BMI, disease status, and ancestry percentage. IA Low risk was the reference category. *Bonferroni corrected *P* value threshold $P \leq 0.004$.

Bold text denotes significant *P* values (<0.05).

the reference category), for the codominant, dominant, and recessive models, adjusted for age, sex, BMI, disease status, and ancestry percentage, showed a statistically significant association of the *ADRB1* gene with high-risk AI, (OR = 2.94, IC 95% 1.64–5.24; $P < 0.0001$) for the Arg/Gly variant, for the dominant model an OR = 2.96 (IC 95% 1.67–5.25; $P < 0.0001$) (Table 5).

4. Discussion and Conclusions

Identification of the genes involved in the metabolic alterations produced in complex diseases like MetS should be a priority to study. We include in the study SNPs of genes related to glucose metabolism [22, 23], fatty acid metabolism, and development of an atherogenic profile in MetS patients.

The main findings of this study are that the *ADRB1* gene heterozygote and dominant model showed an association with high risk AI, with an OR of 2.94 (IC 95% 1.64–5.24; $P < 0.0001$) for the Arg/Gly variant, for the dominant model an OR of 2.96 (IC 95% 1.67–5.25; $P < 0.0001$), and for the Log additive model an OR of 2.52 (IC 95% 1.54–4.15; $P < 0.0001$).

The *ADRB1* gene association is in agreement with reports that associate this gene variant with fat accumulation, BMI, and obesity [18]. The significant association of Arg389Gly variant means that carriers of these polymorphisms are almost three times more likely to present a high-risk AI than noncarriers. These associations are independent of age, sex, BMI, and ancestry percentage. These observations are supported by studies that associated the variant with a poor coupling of the receptor with the G-protein, which translates

TABLE 5: Association of polymorphism *ADRB1* rs1801253 with atherogenic index.

SNP	Medium risk AI ORa (CI)	<i>P</i>	High risk AI ORa (CI)	<i>P</i>
C/G	1.08 (0.83, 1.41)	0.55	2.94 (1.64, 5.24)	<0.0001*
G/G	2.19 (0.81, 5.95)	0.12	3.40 (0.39, 29.61)	0.27
^d C/G + G/G	1.12 (0.87, 1.46)	0.36	2.96 (1.67, 5.25)	<0.0001*
^r G/G	2.16 (0.79, 5.84)	0.13	2.47 (0.29, 21.27)	0.40
Log additive	1.16 (0.91, 1.47)	0.22	2.52 (1.54, 4.15)	<0.0001*

Adjusted for age, sex, BMI, Disease status, and ancestry percentage. IA Low risk was the Reference category. *Bonferroni corrected *P* value threshold $P \leq 0.025$. ^dDominant model. ^rRecessive model.

Bold text denotes significant *P* values (<0.05).

to functional consequences [24]. Associations between the *ADRB1* gene Arg389Gly polymorphism and heart diseases and an increase in fat accumulation have also been found [25].

The *HHEX* T/C heterozygote and the dominant model showed an association although not significant with an increase in total cholesterol levels and in LDL-c levels, suggesting that carriers of this variant may be prone to develop lipid metabolism alterations. This is consistent with recent results for the Mexican population [23]. The *HHEX* gene regulates pancreatic development by controlling endodermic cell proliferation and the positioning of the cells that will later turn into pancreatic tissue. This probably occurs through the effects of *HHEX* on the transcription and translation of the cell proliferator. *HHEX* expression remains activated in the adult pancreas, which suggests that *HHEX* may have additional functions in differentiated pancreatic cells. Because the *HHEX* gene plays a role in pancreas development, as described above, it may be involved in glucose metabolism [25]. Some *HHEX* gene variants have been strongly associated with T2D and insulin-stimulated glucose release [26].

The results of the evaluation of the effects of the polymorphic variants on the IR biochemical markers (glucose, insulin, and HOMA-IR) showed that the *IRS1* Gly/Arg variant is associated although not significant with an increase in HOMA-IR, consistent with previous reports of an association between the *IRS1* gene Gly972Arg polymorphism and IR, and with a higher risk of T2D and CVD in various populations, including the Mexican group, where this association was replicated [27–29]. Some studies suggest that this polymorphism may contribute to IR development due to impairment in the insulin ability to activate the *IRS1*/PI3-kinase/Akt/GSK-3 signaling pathway, causing deficient glucose transportation, translocation of glucose transporters, and glycogen synthesis [28].

We found no significant association with PPAR γ Pro12Ala polymorphism; this is contrary to previous studies which report that Ala12 homozygotes have an increased risk of cardiovascular disease (CAD), but a meta-analysis conducted to investigate the relationship between the PPAR γ polymorphism and the potential risk of CAD reported that this risk is higher in Caucasian populations compared to a Asiatic population, suggesting that the risk for cardiovascular

disease conferred by the Pro12Ala polymorphism differs across ethnic populations [30].

Even TCF7L2 may contribute not only to the development of T2DM but also to the development of CAD because its important role in vascular remodeling through the regulation of smooth muscle cell proliferation and endothelial cell growth [31, 32]; in our study, we did not find significant association. Our result is similar to a recent report by the Atherosclerosis Risk in Communities (ARIC) study where they did not find significant associations between TCF7L2 SNPs and incident vascular events [33].

The results of this assessment of the effects of the polymorphic variants on the medium or high risk of atherogenesis confirm the association between the *ADRB1* gene Arg389Gly [17]. Our results suggest that the *ADRB1* gene Arg389Gly polymorphism can be a good biological marker to predict the risk of cardiovascular diseases development given a high-risk AI. This is in agreement with the notion that the genetic susceptibility to atherosclerosis is due in part to known metabolic risk factors (in this case dyslipidemia) [34]. Further studies of this genetic effect are required to evaluate its potential interaction with other risk factors involved in the same metabolic pathway, since the known genetic risk factors do not fully explain the hereditary propensity to atherosclerosis [34].

Abbreviations

AI:	Atherogenic index
AIM:	Ancestry informative markers
BMI:	Body mass index
CVD:	Cardiovascular diseases
DBP:	Diastolic blood pressure
HDL:	High density lipoproteins
HOMA-IR:	Homeostasis model assessment-insulin resistance
IR:	Insulin resistance
LDL:	Low density lipoproteins
MetS:	Metabolic syndrome
SBP:	Systolic blood pressure
T2D:	Type 2 diabetes
VLDL:	Very low density lipoproteins.

Conflict of Interests

There is no conflict of interests that could be perceived as prejudicing the impartiality of the research reported.

Authors' Contribution

B. I. Estrada-Velasco and A. I. Burguete-García have equal contribution.

Acknowledgments

This work was supported by a Grant from CONACYT SALUD (2005-C02-14412). Proyectos Estratégicos; IMSS-2004/014, 2005/2/I/363, and 2006/1B/1/002, Fundación IMSS

A. C. Fundación Gonzalo Río Arronte I. A. P. Mexico, and the "Vinculación del Cinvestav con el Sector Salud" Support Program, 2006. M. Cruz is a recipient of a Fundación IMSS Scholarship, Mexico.

References

- [1] R. H. Eckel, S. M. Grundy, and P. Z. Zimmet, "The metabolic syndrome," *The Lancet*, vol. 365, no. 9468, pp. 1415–1428, 2005.
- [2] S. M. Grundy, J. I. Cleeman, S. R. Daniels et al., "Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement," *Circulation*, vol. 112, no. 17, pp. 2735–2752, 2005.
- [3] C. M. Phillips, A. C. Tierney, and H. M. Roche, "Gene-nutrient interactions in the metabolic syndrome," *Journal of Nutrigenetics and Nutrigenomics*, vol. 1, no. 3, pp. 136–151, 2008.
- [4] R. W. Nesto, "Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome," *American Journal of Cardiovascular Drugs*, vol. 5, no. 6, pp. 379–387, 2005.
- [5] K. F. Petersen, S. Dufour, D. Befroy, R. Garcia, and G. I. Shulman, "Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes," *The New England Journal of Medicine*, vol. 350, no. 7, pp. 664–671, 2004.
- [6] B. Isomaa, P. Almgren, T. Tuomi et al., "Cardiovascular morbidity and mortality associated with the metabolic syndrome," *Diabetes Care*, vol. 24, no. 4, pp. 683–689, 2001.
- [7] R. Rojas, C. A. Aguilar-Salinas, A. Jiménez-Corona et al., "Metabolic syndrome in Mexican adults. Results from the National Health and Nutrition Survey 2006," *Salud Publica de Mexico*, vol. 52, supplement 1, pp. S11–S18, 2010.
- [8] I. Prokopenko, M. I. McCarthy, and C. M. Lindgren, "Type 2 diabetes: new genes, new understanding," *Trends in Genetics*, vol. 24, no. 12, pp. 613–621, 2008.
- [9] S. Canizales-Quinteros, C. A. Aguilar-Salinas, M. G. Ortiz-López et al., "Association of PPARG2 Pro12Ala variant with larger body mass index in Mestizo and Amerindian populations of Mexico," *Human Biology*, vol. 79, no. 1, pp. 111–119, 2007.
- [10] M. Ghossaini, D. Meyre, S. Lobbens et al., "Implication of the Pro12Ala polymorphism of the PPAR-gamma 2 gene in type 2 diabetes and obesity in the French population," *BMC Medical Genetics*, vol. 6, article 11, 2005.
- [11] J. Robitaille, C. Brouillette, A. Houde et al., "Association between the PPAR α -L162V polymorphism and components of the metabolic syndrome," *Journal of Human Genetics*, vol. 49, no. 9, pp. 482–489, 2004.
- [12] K. Kristiansson, M. Perola, E. Tikkanen et al., "Genome-wide screen for metabolic syndrome susceptibility loci reveals strong lipid gene contribution but no evidence for common genetic basis for clustering of metabolic syndrome traits," *Circulation Cardiovascular Genetics*, vol. 5, no. 2, pp. 242–249, 2012.
- [13] M. L. Hribal, M. Federici, O. Porzio et al., "The Gly $\rightarrow$ Arg⁹⁷² amino acid polymorphism in insulin receptor substrate-1 affects glucose metabolism in skeletal muscle cells," *Journal of Clinical Endocrinology and Metabolism*, vol. 85, no. 5, pp. 2004–2013, 2000.
- [14] M. A. Marini, S. Frontoni, D. Mineo et al., "The Arg⁹⁷² variant in insulin receptor substrate-1 is associated with an atherogenic profile in offspring of type 2 diabetic patients," *Journal of Clinical Endocrinology and Metabolism*, vol. 88, no. 7, pp. 3368–3371, 2003.
- [15] R. Sladek, G. Rocheleau, J. Rung et al., "A Genome-Wide Association Study identifies novel risk loci for type 2 diabetes," *Nature*, vol. 445, no. 7130, pp. 881–885, 2007.
- [16] Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes for BioMedical Research, "Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels," *Science*, vol. 316, article 5829, pp. 1331–1336, 2007.
- [17] J. V. van Vliet-Ostaptchouk, N. C. Onland-Moret, T. W. van Haeften et al., "HHEX gene polymorphisms are associated with type 2 diabetes in the Dutch Breda cohort," *European Journal of Human Genetics*, vol. 16, no. 5, pp. 652–656, 2008.
- [18] I. J. Dionne, M. J. Garant, A. A. Nolan et al., "Association between obesity and a polymorphism in the β 1-adrenoceptor gene (Gly389Arg ADRB1) in Caucasian women," *International Journal of Obesity*, vol. 26, no. 5, pp. 633–639, 2002.
- [19] W. P. Castelli, "Lipids, risk factors and ischaemic heart disease," *Atherosclerosis*, vol. 124, pp. S1–S9, 1996.
- [20] V. L. Martinez-Marignac, A. Valladares, E. Cameron et al., "Admixture in Mexico City: implications for admixture mapping of type 2 diabetes genetic risk factors," *Human Genetics*, vol. 120, no. 6, pp. 807–819, 2007.
- [21] S. Wacholder, S. Chanock, M. Garcia-Closas, L. El Ghormli, and N. Rothman, "Assessing the probability that a positive report is false: an approach for Molecular Epidemiology Studies," *Journal of the National Cancer Institute*, vol. 96, no. 6, pp. 434–442, 2004.
- [22] M. Cruz, J. García-Mena, E. López et al., "Genes candidatos como posibles marcadores de susceptibilidad a Diabetes tipo 2," *REB*, vol. 24, pp. 81–86, 2005.
- [23] M. Cruz, A. Valladares, J. Garcia-Mena et al., "Candidate Gene Association Study conditioning on individual ancestry in type 2 diabetes and metabolic syndrome patients from Mexico City," *Diabetes/Metabolism Research and Reviews*, vol. 26, no. 4, pp. 261–270, 2010.
- [24] D. A. Mason, J. D. Moore, S. A. Green, and S. B. Liggett, "A gain-of-function polymorphism in a G-protein coupling domain of the human β 1-adrenergic receptor," *Journal of Biological Chemistry*, vol. 274, no. 18, pp. 12670–12674, 1999.
- [25] S. Podlowski, K. Wenzel, H. P. Luther et al., " β 1-adrenoceptor gene variations: a role in idiopathic dilated cardiomyopathy?" *Journal of Molecular Medicine*, vol. 78, no. 2, pp. 87–93, 2000.
- [26] H. Staiger, A. Stančáková, J. Zilinskaite et al., "A candidate type 2 diabetes polymorphism near the HHEX locus affects acute glucose-stimulated insulin release in European populations results from the EUGENE2 Study," *Diabetes*, vol. 57, no. 2, pp. 514–517, 2008.
- [27] A. I. Burguete-Garcia, M. Cruz-Lopez, V. Madrid-Marina et al., "Association of Gly972Arg polymorphism of IRS1 gene with type 2 diabetes mellitus in lean participants of a national health survey in Mexico: a Candidate Gene Study," *Metabolism Clinical and Experimental*, vol. 59, no. 1, pp. 38–45, 2010.
- [28] G. Sesti, M. Federici, M. L. Hribal, D. Lauro, P. Sbraccia, and R. Lauro, "Defects of the Insulin Receptor Substrate (IRS) system in human metabolic disorders," *The FASEB Journal*, vol. 15, no. 12, pp. 2099–2111, 2001.
- [29] L. E. Martínez-Gómez, M. Cruz, G. A. Martínez-Nava et al., "A replication study of the IRS1, CAPN10, TCF7L2, and PPARG gene polymorphisms associated with type 2 diabetes in two different populations of Mexico," *Annals of Human Genetics*, vol. 75, no. 5, pp. 612–620, 2011.

- [30] Z. Wu, Y. Lou, W. Jin, Y. Liu, L. Lu, and G. lu, "The Pro12Ala polymorphism in the peroxisome proliferator-activated receptor gamma-2 gene (PPARc2) is associated with increased risk of coronary artery disease: a meta-analysis," *PLoS ONE*, vol. 7, no. 12, Article ID e53105, 2012.
- [31] A. Muendlein, C. H. Saely, S. Geller-Rhomberg et al., "Single nucleotide polymorphisms of TCF7L2 are linked to diabetic coronary atherosclerosis," *PLoS ONE*, vol. 6, no. 3, Article ID e17978, 2011.
- [32] X. Wang, Y. Xiao, Y. Mou, Y. Zhao, W. M. Blankesteyn, and J. L. Hall, "A role for the β -catenin/T-cell factor signaling cascade in vascular remodeling," *Circulation Research*, vol. 90, no. 3, pp. 340–347, 2002.
- [33] S. J. Bielinski, J. S. Pankow, A. R. Folsom, K. E. North, and E. Boerwinkle, "TCF7L2 single nucleotide polymorphisms, cardiovascular disease and all-cause mortality: the Atherosclerosis Risk in Communities (ARIC) Study," *Diabetologia*, vol. 51, no. 6, pp. 968–970, 2008.
- [34] S. Kovacic and M. Bakran, "Genetic susceptibility to atherosclerosis," *Stroke Research and Treatment*, vol. 2012, Article ID 362941, 5 pages, 2012.